DDInter298 DDInter133
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal side effects and long term benefits, has resulted in wide use of this medication in North America.[A181087, A181406] Atorvastatin and other statins including [lovastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line treatment options for dyslipidemia.[A181087, A181406] The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) (such as heart attack, atherosclerosis, angina, peripheral artery disease, and stroke) in many countries. An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.[A181087,A181553] Several landmark studies demonstrate that the use of statins is associated with both a reduction in LDL levels and CVD risk.[A181090,A181093,A181096,A181427,A181475,A181538] Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Some evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within five years) statin use leads to a 20%-22% relative reduction in the number of major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. It is a pentasubstituted pyrrole formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound. Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation.
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atorvastatin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} (Compound) resembles {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) regulates {v} (Gene) ABCC5
ABCC5 {u} (Gene) is bound by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) regulates {v} (Gene) FOXO4
FOXO4 {u} (Gene) is upregulated by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is associated with {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) regulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Atorvastatin
Carboplatin {u} (Compound) treats {v} (Disease) uterine cancer
uterine cancer {u} (Disease) is treated by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Atorvastatin
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Atorvastatin (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with ABCB1 (Gene) and ABCB1 (Gene) is bound by Atorvastatin (Compound)
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) regulates ABCC5 (Gene) and ABCC5 (Gene) is bound by Atorvastatin (Compound)
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) regulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Atorvastatin (Compound)
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is associated with MYC (Gene) and MYC (Gene) is downregulated by Atorvastatin (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Atorvastatin (Compound)
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) regulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Atorvastatin (Compound)
Carboplatin (Compound) treats uterine cancer (Disease) and uterine cancer (Disease) is treated by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Atorvastatin